EduAsiaNews, Tokyo — The field of dentistry is witnessing an unprecedented new chapter. Researchers at Kyoto University, Japan, have successfully developed an antibody-based drug claimed to stimulate the regrowth of permanently lost human teeth. This breakthrough is not merely a laboratory innovation; it is currently being tested directly in humans through an official clinical trial—the first of its kind in the world.
The drug works by inhibiting the USAG-1 protein, a protein known to suppress the development of tooth buds in adult humans. The antibody, named TRG035, is designed to “unlock” dormant tooth buds, allowing the body to restart the natural process of tooth growth. The foundational research behind this discovery has been underway for more than a decade at Kyoto University laboratories before being deemed mature enough for human trials.
The Phase 1 clinical trial, conducted at Kyoto University Hospital, began on October 18, 2024, under the leadership of Dr. Katsu Takahashi. A total of 30 adult male volunteers aged 30 to 64, who had lost at least four congenital molars, were selected as participants. Each received a single intravenous dose and was closely monitored through imaging examinations to detect activation of tooth buds as well as their immune responses.
As of April 2026, the trial, focused on safety and pharmacokinetic, has successfully passed its initial phase with encouraging results. No serious side effects have been reported. Researchers expressed confidence that these early findings pave the way for broader subsequent clinical trials before the drug can eventually be introduced as an official therapeutic option for millions of people worldwide who have lost teeth due to various causes.
If proven safe and effective in the next stages, TRG035 has the potential to revolutionize how the medical world treats permanent tooth loss, a condition that has so far only been addressed through artificial implants or dentures. This achievement by Kyoto University further reinforces Japan’s position as a global leader in regenerative medicine research, where academic discoveries do not remain on paper but are translated into real solutions for human life. (**)
